News
MedPage Today on MSN6d
Alzheimer's Benefits Continue With Donanemab for 3 Years, Long-Term Data Show
Mean amyloid levels remained below 24.1 centiloids at 3 years for participants who completed donanemab treatment by 52 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback